Replies to post #8851 on InMed Pharmaceuticals Inc (INM)

[lesgetrich]

There is a market for THC and CBD but not much of one yet for the minor cannabinoids, so before inmed counts its revenue for biosynthesis they need to create a market.

They can do this by creating smaller batches of these cannabinoids and charging a bundle to sell them for research. They would be the main, and possibly only, source for these research supplies. They also have a Bioinformatics program that can point researches in the right direction (i.e. which cannabinoids might be effective for which conditions).